Indivior PLC Stock Forecast for 2023 - 2025 - 2030
Updated on 02/01/2023
Indivior PLC Stock Forecast and Price Target
The average target price set lately by experts for Indivior PLC to reach by the end of the year is £4.74, which would imply a potential downside of approximately -97.4 percent from the previous closing price if it were to be achieved. This prediction is based on a high estimate of £5.09 and a low estimate of £3.93. Even if you are not interested in INDV stock, you should still be aware of its competitors.
-97.40% Downside
Indivior PLC Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Indivior PLC's Price has decreased from £2.13 to £1.67 – a 21.74% drop! The next year looks promising for Indivior PLC, with analysts predicting Fair Value of £2.09 – an increase of 25.46%. Over the next nine years, experts anticipate that Indivior PLC's Fair Value will grow at a rate of 26.02%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$344.15 | $333.19 | 16.23% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$44.16 | $53.97 | 19.23% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
8
|
£10.59k | £153.20 | -98.53% |
| GMAB Stock Forecast | Genmab A/S | Outperform |
16
|
kr3.00k | kr2.84k | -8.24% |
| ARGX Stock Forecast | argenx | Buy |
4
|
358.10€ | 0.00€ | -0.31% |
Indivior PLC Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Indivior PLC's Revenue has grown, increasing from £785.00M to £791.00M – a growth of 0.76%. The next year, 0 experts forecast that Indivior PLC's Revenue will decrease by 5.02%, reaching £751.27M. In 2030, professionals predict that Indivior PLC's Revenue will decrease by 5.03%, reaching £751.19M.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| TEVA Stock Forecast | Teva Pharmaceutical Industries | Hold |
12
|
$10.54 | $12.04 | -5.12% |
| REC Stock Forecast | Recordati Industria Chimica e ... | Hold |
18
|
38.68€ | 49.03€ | 13.75% |
| ORNBV Stock Forecast | Orion Oyj | Hold |
14
|
53.46€ | 34.70€ | -25.18% |
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ITCI Stock Forecast | Intra-Cellular Therapies | Outperform |
10
|
$47.92 | $68.92 | 46.08% |
| HIK Stock Forecast | Hikma Pharmaceuticals PLC | Outperform |
18
|
£1.71k | £29.33 | -98.39% |
| ALKS Stock Forecast | Alkermes | Hold |
10
|
$27.11 | $0.00 | 18.04% |
Indivior PLC Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, Indivior PLC's Free Cash Flow has grown by 142.36%, rising from £144.00M to £349.00M. According to 0 prominent analysts, Indivior PLC's Free Cash Flow will fall by 47.54% in the next year, reaching £183.09M. By 2030, professionals believe that Indivior PLC's Free Cash Flow will decrease by 35.42%, reaching £225.38M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| LUN Stock Forecast | H. Lundbeck A/S | Outperform |
18
|
kr23.88 | kr224.81 | 716.58% |
| ALK B Stock Forecast | ALK-Abelló A/S | Hold |
13
|
kr96.05 | kr3.35k | 84.80% |
| EVT Stock Forecast | Evotec | Outperform |
14
|
18.92€ | 37.33€ | 74.42% |
Indivior PLC Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Indivior PLC's Net Income has grown from £134.00M to £205.00M – a 52.99% increase. For the next year, 0 analysts project Indivior PLC's Net Income to drop by 51.29%, reaching £99.86M. By 2030, professionals believe that Indivior PLC's Net Income will decrease by 36.85%, reaching £129.46M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ALM Stock Forecast | Almirall | Outperform |
16
|
9.26€ | 14.28€ | 51.19% |
| CLIN Stock Forecast | Clinigen Group | Outperform |
18
|
£9.25 | £7.78 | 75.89% |
| FAE Stock Forecast | Faes Farma | Hold |
18
|
3.44€ | 4.20€ | 22.09% |
Indivior PLC EBITDA Forecast for 2023 - 2025 - 2030
Indivior PLC's EBITDA has decreased In the last two years, from £214.00M to £198.00M – a 7.48% drop. For next year, analysts predict EBITDA of £207.17M, which would mean an increase of 4.63%. Over the next nine years, experts predict that Indivior PLC's EBITDA will grow at a rate of 3.34%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| VEC Stock Forecast | Vectura Group | Hold |
14
|
£165.00 | £1.41 | -98.88% |
| PHM Stock Forecast | Pharma Mar | Outperform |
13
|
60.52€ | 0.00€ | 35.82% |
| COPN Stock Forecast | Cosmo Pharmaceuticals N.V. | Buy |
12
|
CHF56.10 | CHF0.00 | 65.54% |
Indivior PLC EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Indivior PLC's EBIT has seen a drop from £202.00M to £186.00M – a 7.92% decrease. In the next year, analysts believe that EBIT will reach £200.99M – an increase of 8.06%. For the next nine years, the forecast is for EBIT to grow by 6.72%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ZEAL Stock Forecast | Zealand Pharma A/S | Outperform |
8
|
kr117.00 | kr241.83 | 70.94% |
| MOR Stock Forecast | MorphoSys | Outperform |
6
|
18.38€ | 40.70€ | 87.70% |
| VNDA Stock Forecast | Vanda Pharmaceuticals | Hold |
0
|
$7.60 | $24.00 | 31.58% |
Indivior PLC EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Indivior PLC's EPS has decreased from £0.23 to £0.18 – a 21.74% drop! The next year looks promising for Indivior PLC, with analysts predicting EPS of £0.23 – an increase of 25.46%. Over the next nine years, experts anticipate that Indivior PLC's EPS will grow at a rate of 26.02%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| NasdaqGS:BDSI Stock Forecast | BioDelivery Sciences Internati... | - |
11
|
$5.59 | $10.00 | 78.89% |
| BSLN Stock Forecast | Basilea Pharmaceutica | Buy |
6
|
CHF42.26 | CHF87.60 | 72.74% |
| DBV Stock Forecast | DBV Technologies | Outperform |
5
|
4.48€ | 12.23€ | -11.83% |